 CytoDyn Inc said it has received comments from the US Food and Drug Administration FDA on the companys recently submitted dose justification report for its Vyrologix leronlimab-PRO 140 drug, an important component to the companys resubmission of its Biologics License Application BLA for HIV. The Vancouver, Washington-based late-stage biotechnology company is working to develop a significant advance in HIV treatment beyond the AIDS cocktail combination of pills that has kept millions of people alive since the mid-1990s. 